Diaceutics (LON:DXRX) Trading 0.8% Higher – Still a Buy?

Diaceutics PLC (LON:DXRX) shot up 0.8% during mid-day trading on Monday . The stock traded as high as GBX 128.25 ($1.67) and last traded at GBX 128.25 ($1.67). 58,412 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 126,544 shares. The stock had previously closed at GBX 127.20 ($1.65).

Analysts Set New Price Targets

Several brokerages have issued reports on DXRX. Canaccord Genuity Group restated a “buy” rating and issued a GBX 160 ($2.08) price target on shares of Diaceutics in a research report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 160 ($2.08) price objective on shares of Diaceutics in a research note on Tuesday, December 17th.

Diaceutics Stock Performance

The firm has a market capitalization of £108.24 million, a P/E ratio of -38.04 and a beta of 0.58. The company’s 50 day moving average is GBX 139.88 and its 200-day moving average is GBX 130.55. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39.

Insider Buying and Selling

In other Diaceutics news, insider Graham Paterson acquired 11,643 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were purchased at an average cost of GBX 138 ($1.79) per share, with a total value of £16,067.34 ($20,869.39). 34.30% of the stock is owned by insiders.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.